 SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores
SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores
Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores
Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores
IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores
Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores 
              Dermozone, a global wound healing and Herbal Skincare Products Company, announced that it has set up office in Chennai, it's second in India after Bengaluru. The Chennai office, located at Annasalai ,would be an extension of the company's existing Bengaluru office and also be the operations hub for Dermozone in India.
Dermozone, with headquarters in Jakarta, Indonesia had in the last quarter of 2015 announced its entry into the Indian market, by setting up an office in Bengaluru in the name of Indo- Dermozone Herbal Pvt. Ltd. Dermozone also has operations in UK, USA, Japan, Russia, Seoul, China, Taiwan, Hong Kong, South Africa, Brazil, Argentina, Mexico, Chile, Australia and Dubai (Middle East).
"We are extremely pleased to announce the opening of our Chennai office and would be very soon unveiling in India our renowned herbal Skincare products under our two brands -'MedCare' and 'BodyCare'." said Mr. K.S. Dharshan, Chairman & CEO of Dermozone." 'MedCare' brand comprises of four products- WoundCare (wound and burn), VaginyCare (feminine usage), BabyCare (allergies, rashes etc) and MedCare Soap. 'BodyCare' caters to the cosmetics and beauty care market with a range of seventeen products."
"Dermozone had recently announced that it had developed 'dalethyne ', a revolutionary chemical molecule compound, proven as an antimicrobial agent against most of the bacteria, fungi and yeasts. Dermozone's best kept secret, 'dalethyne 'will be the key ingredient in the company's MedCare and BodyCare range of herbal products soon to be launched in India." said Mr. Manjunatha K.G, Chief Operation Officer of Indo- Dermozone Herbal Pvt. Ltd. "Currently, Dermozone's MedCare product 'WoundCare' is under clinical trial at Apollo Hospitals, Chennai and expected to be completed by the second quarter of 2016."